The lawsuit, spearheaded by the Rosen Law Firm, alleges that PROCEPT BioRobotics misled shareholders by inflating sales figures through an undisclosed discount program. According to the complaint, the company incentivized customers to place bulk orders far exceeding actual procedure demand. This strategy allegedly created a surplus of over 10,000 excess handpiece units in field inventory by the end of the Class Period, artificially inflating reported revenue while masking the company's true financial health.

Plaintiffs contend that these deceptive practices left the company unable to meet its 2025 financial guidance, ultimately causing significant losses for shareholders when the market learned the true extent of the overstocking. Investors interested in the case can contact Phillip Kim at the Rosen Law Firm to discuss their options. While a lawsuit has been filed, no class has been certified, meaning investors may choose their own counsel or remain absent class members without forfeiting their right to potential future recoveries.